David Bond

30PUBLICATIONS
224CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Aug 24, 2026
Incidence of clinically significant chemotherapy induced nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis.

|Jul 10, 2026
Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study.

|Feb 04, 2026
Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate.

Zachary J Arnold, Jordan Lundberg, Tracy Wiczer

|Dec 11, 2025
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Yucai Wang, Melissa C Larson, Steven R Hwang

|Nov 25, 2025
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.

Jia Ruan, David A Bond, Bijal Shah

|Jul 01, 2025
Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma.

John Sharp, Qiuhong Zhao, Timothy J Voorhees

Pageof 5

Frequent Collaborators

10 joint publications

Narendranath Epperla

9 joint publications

Yazeed Sawalha

7 joint publications

Reem Karmali

5 joint publications

Timothy Voorhees